MACCURA BIOTECHNOLOGY CO.LTD Maccura Biotechnology Co.Ltd Stock
Equities
300463
CNE1000020H3
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.57 CNY | +3.63% |
|
+5.45% | -16.59% |
| Sales 2024 * | 3.24B 447M | Sales 2025 * | 3.59B 496M | Capitalization | 7.7B 1.06B |
|---|---|---|---|---|---|
| Net income 2024 * | 477M 65.9M | Net income 2025 * | 671M 92.71M | EV / Sales 2024 * | 2.38 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.15 x |
| P/E ratio 2024 * |
16.1
x | P/E ratio 2025 * |
11.4
x | Employees | 3,016 |
| Yield 2024 * |
2.23% | Yield 2025 * |
3.34% | Free-Float | 61.17% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.63% | ||
| 1 week | +5.45% | ||
| Current month | -0.71% | ||
| 1 month | -4.12% | ||
| 3 months | -1.26% | ||
| 6 months | -11.48% | ||
| Current year | -16.59% |
1 week
11.50
12.75
1 month
11.4013.18
Current year
9.9015.23
1 year
9.9017.40
3 years
9.9049.34
5 years
9.9065.24
10 years
9.9065.24
| Managers | Title | Age | Since |
|---|---|---|---|
Ming Jian Wu
CEO | Chief Executive Officer | 49 | 01-12-31 |
Shan Yin
DFI | Director of Finance/CFO | 44 | 21-10-25 |
Yong Tang
CHM | Chairman | 60 | 94-10-19 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dai Guo Fu
BRD | Director/Board Member | 60 | 19-01-21 |
Yong Tang
CHM | Chairman | 60 | 94-10-19 |
Qi Lin Liu
BRD | Director/Board Member | 57 | 93-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 12.57 | +3.63% | 8 292 144 |
| 24-04-24 | 12.13 | +0.92% | 2,669,366 |
| 24-04-23 | 12.02 | +0.84% | 4,089,861 |
| 24-04-22 | 11.92 | +2.23% | 6,193,587 |
| 24-04-19 | 11.66 | -0.93% | 3,565,969 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Maccura Biotechnology Co., Ltd., formerly Sichuan Maccura Biotechnology Co., Ltd., is a China-based company principally engaged in research, development, manufacture and sales of in-vitro diagnostics products and the sales of in-vitro diagnostic products of foreign brands as an agent. The Company provides hundreds of products which cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.
Calendar
2024-04-24
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.57
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.59% | 1.03B | |
| -1.09% | 12.72B | |
| -12.53% | 7.5B | |
| +0.45% | 5.48B | |
| -1.37% | 4.61B | |
| +4.38% | 4.47B | |
| -52.07% | 3.28B | |
| +11.34% | 2.71B | |
| -19.05% | 2.02B | |
| -11.07% | 1.74B |
- Stock Market
- Equities
- 300463 Stock
